Skip to content

A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity

Ramiro Solis

Zenodo (CERN European Organization for Nuclear Research) June 24, 2026 Peer reviewed DOI: 10.5281/zenodo.20824129 via OpenAlex

Summary

Neuroplasticity, the brain's ability to adapt, declines with age, leading to cognitive inflexibility. This paper examines whether the decline of DMT, a compound that promotes synaptic growth and neurogenesis, contributes to this loss of neuroplasticity. While DMT levels are highest in development and decrease with age, evidence regarding its physiological role is mixed. The study proposes further research to determine if DMT depletion directly causes reduced plasticity or if their relationship is coincidental.

Study at a glance

Key finding The hypothesis that DMT depletion may contribute to age-related loss of neuroplasticity is proposed for further investigation.

Abstract

The brain’s ability to rewire itself, neuroplasticity, declines dramatically with age. Children learn faster; adults get stuck in patterns; older adults struggle to adapt. The reasons for this decline remain unclear. In a companion paper (Solis, 2026a), I critically evaluated the broad hypothesis that N,N-dimethyltryptamine (DMT) has endogenous physiological functions. The evidence was found to be mixed and contested. This paper narrows the focus to a specific, testable hypothesis: that DMT may play a role in maintaining neuroplasticity, and that its decline may contribute to the age-related loss of cognitive flexibility. DMT is known to promote synaptic growth, neurogenesis, and BDNF expression in animal models. DMT levels are reportedly highest during development and decline with age. However, the evidence is mixed and contested. Barker (2025) reports DMT concentrations in the nM range, comparable to serotonin and dopamine. Palner et al. (2026) report that DMT is below the detection limit in rat brain. The sigma-1 receptor affinity (Ki ~14 μM) is three orders of magnitude higher than reported physiological concentrations. The intracellular 5-HT2A receptor finding (Barker 2025) has not been independently replicated. The dietary DMT gap has not been directly measured. Clinical trials demonstrate that high-dose DMT produces antidepressant effects (Erritzoe et al. 2026; Falchi-Carvalho et al. 2025), but clinical efficacy does not establish endogenous function. The paper does not claim the hypothesis is established; it critically evaluates the evidence and proposes a research program to test whether DMT depletion is a cause of lost plasticity, or whether the relationship is incidental.

Tags

Comments

No comments yet.

Log in to comment